The latest delay in the Keystone XL pipeline is all about politics, and not about the reality of pipelines, said John Hofmeister.» Read More
El Nino could cause some commodity prices to rise and others to fall, reports CNBC's Jane Wells.
Jim Pethokoukis, American Enterprise Institute, shares his thoughts on whether the government is making the student loan crisis worse.
Seventy percent of the JetBlue pilots have voted to join ALPA, reports CNBC's Phil LeBeau.
Robert Olstein, Olstein Capital Management, and Herb Greenberg, CNBC contributor, discuss whether some companies are abusing how they report quarterly results.
Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.
CNBC's "Earnings Squad," has a look at three names to watch before they report earnings.
Jed Kolko, Trulia chief economist, discusses whether home ownership is the best long-term investment for most Americans.
CNBC's Diana Olick takes a look at what's prompting the slump in existing home sales.
CNBC's Meg Tirrell; Herb Greenberg, CNBC contributor, and Arindam Nag, Mergermarket, discuss potential takeover targets in the pharmaceutical space.
Discussing a report Nike fired its entire FuelBand crew, and when wearables will be embraced, with Lauren Goode, Re/code tech reporter.
Reports indicate Ford is said to name Mark Fields as the next CEO of the auto company, with CNBC's Phil LeBeau.
What to expect from the earnings of Netflix, AK Steel, McDonald's and Simon Property Group, with CNBC's Melissa Lee, Courtney Reagan and Dominic Chu.
Discussing another delay for the Keystone XL pipeline, and the politics involved in moving the project forward, with John Hofmeister, former Shell Oil president.
Supporters of the Keystone Pipeline say it is critical to the North American oil boom, reports CNBC's Jackie DeAngelis. The Obama administration has added an additional delay in the program.
Discussing the pullback in biotech, with Paul Hickey, Bespoke Investment Group.
Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.
Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.
Sarepta Therapeutics got the go-ahead to file for approval of its experimental drug for Duchenne muscular dystrophy.
CNBC's Meg Tirrell reports on a new scientific discovery for the more than $1.7 billion U.S. business of in vitro fertilization. Robert Frank provides insight.
CNBC's John Harwood reflects on the last 25 years in D.C., as well as Texas Gov. Rick Perry's debate gaffe.